Q1 Earnings Forecast for BrainsWay Issued By Northland Capmk

BrainsWay Ltd. (NASDAQ:BWAY) – Equities research analysts at Northland Capmk cut their Q1 2025 EPS estimates for shares of BrainsWay in a research report issued to clients and investors on Tuesday, March 11th. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings per share of $0.01 for the quarter, down from their prior estimate of $0.02. The consensus estimate for BrainsWay’s current full-year earnings is $0.08 per share. Northland Capmk also issued estimates for BrainsWay’s Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS, FY2025 earnings at $0.08 EPS and FY2026 earnings at $0.15 EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of BrainsWay in a research report on Wednesday.

BrainsWay Stock Performance

BWAY opened at $10.21 on Friday. BrainsWay has a 12-month low of $4.61 and a 12-month high of $11.79. The firm has a market capitalization of $192.22 million, a PE ratio of 102.11 and a beta of 1.29. The firm has a 50 day moving average of $10.26 and a two-hundred day moving average of $9.61.

Hedge Funds Weigh In On BrainsWay

Several institutional investors have recently made changes to their positions in the company. Two Sigma Investments LP increased its holdings in shares of BrainsWay by 2.0% during the 4th quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock valued at $875,000 after purchasing an additional 1,786 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of BrainsWay by 10.8% during the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock valued at $207,000 after purchasing an additional 2,144 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of BrainsWay by 14.6% during the 4th quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock valued at $181,000 after purchasing an additional 2,446 shares in the last quarter. Lazard Asset Management LLC purchased a new position in shares of BrainsWay during the 4th quarter valued at approximately $44,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of BrainsWay by 61.9% during the 4th quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company’s stock valued at $226,000 after purchasing an additional 9,149 shares in the last quarter. 30.11% of the stock is owned by hedge funds and other institutional investors.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.